Start­up with Johns Hop­kins roots rais­ing $40.5 mil­lion to de­vel­op can­cer me­tab­o­lism drugs

A new on­col­o­gy com­pa­ny spun out of Johns Hop­kins School of Med­i­cine is rais­ing up to $40.5 mil­lion to de­vel­op its plat­form of an­ti­cancer ther­a­pies.

The start­up, found­ed just a year ago, is called Dra­cen Phar­ma­ceu­ti­cals, and its tech is based on work by Bar­bara Slush­er, a pro­fes­sor of neu­rol­o­gy, and Jonathan Pow­ell, a pro­fes­sor of on­col­o­gy at Johns Hop­kins School of Med­i­cine.

The re­searchers al­tered the struc­ture of an ex­per­i­men­tal drug that en­hanced its abil­i­ty to slip through the blood-brain bar­ri­er. Their re­search was pub­lished in Au­gust 2016 in the Jour­nal of Med­i­c­i­nal Chem­istry, which showed in an­i­mal stud­ies that the al­tered drug struc­ture re­sult­ed in ten times bet­ter drug de­liv­ery to the brains com­pared with the rest of an­i­mals’ bod­ies.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA